- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02416778
Effect of Intravenous Iron (Ferinject®) on Exercise Capacity and Quality of Life of Stable COPD Patients
Disordered iron metabolism characterizes an important determinant of impaired exercise tolerance and work capacity. Iron-deficiency anemia commonly features impaired aerobic capacity caused by decreased oxygen carrying capacity, and has been associated with a negative effect on dyspnea and walking distance.
Apart from that, iron deficiency without anemia was shown to affect endurance and energetic efficiency via decreased tissue oxidative capacity. Consequently, depleted iron stores could be capable of causing fatigue, breathlessness and impaired exercise tolerance, which are common features of chronic cardiopulmonary diseases like chronic heart failure (CHF) and COPD (Chronic Obstructive Pulmonary Disease). Indeed, a current surge of interest aimed at potential underlying determinants in CHF and COPD independent of the primarily disordered organ.
Recent studies identified iron deficiency without anemia as an independent factor of reduced exercise intolerance in CHF as well as in COPD. Moreover, intravenous iron application significantly improved exercise capacity in CHF patients with iron deficiency in presence as well as in absence of anemia. Comparable to CHF, the daily living of patients with COPD is compromised by impaired exercise tolerance.
However, airflow limitation, as the foremost characteristic of COPD shows only weak associations with exercise capacity. In line with that, exercise capacity showed no remarkable improvement in lung transplant recipients, underlining the presence of systemic determinants of limited exercise tolerance like iron deficiency. The investigators showed that iron deficiency is present in 50% of stable COPD patients (unpublished data), which is according to recently published data.
The investigators presume that iron deficiency contributes to limited exercise capacity in COPD patients. Thus, the aim of this study is to determine whether iv iron is associated with increases exercise capacity in COPD.
Therefore the investigators hypothesize that filling up depleted iron storages will increase exercise capacity, measured by the 6-MWT (Minute Walking Test).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Georg-Christian Funk, M.D.Ass.Prof
- Phone Number: +43 650 31 00 882
- Email: georg-christian.funk@wienkav.at
Study Locations
-
-
-
Vienna, Austria, 1140
- Recruiting
- Otto Wagner Spital, Dep. of Respiratory and Critical Care Medicine
-
Contact:
- Georg-Christian Funk, M.D.
- Phone Number: 882 +43 650 3100882
- Email: georg-christian.funk@wienkav.at
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of chronic obstructive pulmonary disease according to the current guidelines
- Evidence of irreversible airflow obstruction on spirometry (i.e. an increase of less than 200ml and 15% in the post-bronchodilator FEV1)
- 30% < FEV1 < 80% predicted
- Stable COPD medication: no dose changes in COPD medication within last 4 weeks
- Age of 40 to 75 years
- Body mass index < 30 kg/m2
- Iron deficiency:
ferritin <100 ng/mL or ferritin 100-300 ng/mL when TSAT (Transferrin saturation) <20%
- Hb between 9.5 and 13.5 g/dL
- MMRC (Modified Medical Research Council Scale) 0 to 3
- Patient must be able to perform the bicycle exercise test according to investigator
Exclusion Criteria:
- Meeting contraindications of iv iron administration
- Known active infection
- C-reactive protein>20 mg/L
- clinically significant bleeding
- active malignancy
- History of congestive heart failure
- BNP (Brain Natriuretic Peptide) ≥ 250 pg/ml
- Evidence of myocardial ischemia during Cardiopulmonary Exercise Test (CPET) (i.e. chest pain or signs of ischemia in ECG)
- uncontrolled Hypertension
- other clinical significant chronic heart disease
- Acute myocardial infarction or acute coronary syndrome, transient ischaemic attack or stroke within the last 3 months
- History of peripheral artery occlusive disease
- Typical claudication
- Anaemia due to reasons other than iron deficiency (e.g.haemoglobinopathy)
- History of erythropoietin, i.v. or oral iron therapy, and blood transfusion in previous 12 weeks and/or such therapy planned within the next 6 months
- Immunosuppressive therapy or renal dialysis
- ALT (Alanine Aminotransferase) or AST (Aspartate Aminotransferase) >3times upper limit of normal
- Hemochromatosis
- Significant lung diseases other than COPD
- pulmonary hypertension (maximum of velocity tricuspid regurgitation > 2,8m/sec)
- Exacerbation within prior 4 weeks
- > 1 exacerbation within last year
- bronchoscopic lung volume reduction (BLVR)
- Malignancy within the past 5 years
- Autoimmune diseases
- Rheumatoid diseases
- Chronic renal failure (defined through: eGFR (Estimated Glomerular Filtration Rate) < 60 ml/min)
- Active diet
- Physical rehabilitation training
- Pregnancy, breast feeding
- Participation in other therapeutic trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Arm
Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion will be administered in patients with COPD
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efficacy Endpoint: Increased exercise capacity in 6-Minute-Walking-Test (walking distance in meters [m])
Time Frame: Study week 12
|
Study week 12
|
Efficacy Endpoint: Cardiopulmonary Exercise Test (FEV1 [ml] / FVC [% predicted])
Time Frame: Study week 12
|
Study week 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tolerability/Safety Endpoint: Acute COPD exacerbation
Time Frame: Pre-Screening, Study Day 0, Study week1, study week 4, study week 8 and study week 12
|
Pre-Screening, Study Day 0, Study week1, study week 4, study week 8 and study week 12
|
Adverse events of iron administration
Time Frame: Pre-Screening, Study Day 0, Study week1, study week 4, study week 8 and study week 12
|
Pre-Screening, Study Day 0, Study week1, study week 4, study week 8 and study week 12
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Georg-Christian Funk, M.D.Ass.Prof, Otto Wagner Spital, Dep. of Respiratory and Critical Care Medicine, Pavillon Hermann, Sanatoriumstr. 2, A-1140 Vienna
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Iron-COPD Pilotstudy
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Disease, Chronic Obstructive
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion
-
Charite University, Berlin, GermanyUniversity of GöttingenUnknownHeart Failure | Iron-deficiencyGermany
-
Dextra Fertility ClinicUnknown
-
Radha GopalanAmerican Regent, Inc.Enrolling by invitationHeart Failure | Iron-deficiencyUnited States
-
Pharmacosmos A/SCompletedIron Deficiency Anemia | Iron Deficiency AnaemiaUnited States
-
Biocruces Bizkaia Health Research InstituteSociedad Espanola de Angiologia y Cirugia VascularRecruitingAnemia | Peripheral Arterial Occlusive DiseaseSpain
-
Pharmacosmos A/SCompletedIron Deficiency Anemia | Iron Deficiency AnaemiaUnited States
-
Vifor PharmaParexel; ClinStar, LLCCompletedAnemia | Crohn's Disease | Ulcerative Colitis | Iron Deficiency | Inflammatory Bowel Disease | Iron-Deficiency AnemiaAustria
-
Maastricht University Medical CenterVifor PharmaTerminatedPostoperative AnaemiaNetherlands
-
Royal Centre for Defence MedicineUniversity of OxfordCompletedIron-deficiency | Pulmonary Vascular Resistance Abnormality | Ventricular Function | Altitude Hypoxia
-
University of PadovaNot yet recruitingHeart Failure | Iron-deficiency | Vitamin D Deficiency | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III